300 related articles for article (PubMed ID: 33718228)
1. Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With
Handlos Grauslund J; Holmström MO; Jørgensen NG; Klausen U; Weis-Banke SE; El Fassi D; Schöllkopf C; Clausen MB; Gjerdrum LMR; Breinholt MF; Kjeldsen JW; Hansen M; Koschmieder S; Chatain N; Novotny GW; Petersen J; Kjær L; Skov V; Met Ö; Svane IM; Hasselbalch HC; Andersen MH
Front Oncol; 2021; 11():637420. PubMed ID: 33718228
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow.
Holmström MO; Andersen M; Traynor S; Ahmad SM; Lisle TL; Handlos Grauslund J; Skov V; Kjær L; Ottesen JT; Gjerstorff MF; Hasselbalch HC; Andersen MH
Front Immunol; 2023; 14():1240678. PubMed ID: 37662956
[TBL] [Abstract][Full Text] [Related]
3. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.
Holmström MO; Martinenaite E; Ahmad SM; Met Ö; Friese C; Kjær L; Riley CH; Thor Straten P; Svane IM; Hasselbalch HC; Andersen MH
Leukemia; 2018 Feb; 32(2):429-437. PubMed ID: 28676668
[TBL] [Abstract][Full Text] [Related]
4. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
Grauslund JH; Holmström MO; Martinenaite E; Lisle TL; Glöckner HJ; El Fassi D; Klausen U; Mortensen REJ; Jørgensen N; Kjær L; Skov V; Svane IM; Hasselbalch HC; Andersen MH
Front Immunol; 2023; 14():1117466. PubMed ID: 36911725
[TBL] [Abstract][Full Text] [Related]
5. Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.
Kjær L; Cordua S; Holmström MO; Thomassen M; Kruse TA; Pallisgaard N; Larsen TS; de Stricker K; Skov V; Hasselbalch HC
PLoS One; 2016; 11(10):e0165336. PubMed ID: 27764253
[TBL] [Abstract][Full Text] [Related]
6. Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.
Holmström MO; Cordua S; Skov V; Kjær L; Pallisgaard N; Ellervik C; Hasselbalch HC; Andersen MH
Cancer Immunol Immunother; 2020 Feb; 69(2):315-324. PubMed ID: 31915854
[TBL] [Abstract][Full Text] [Related]
7. Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.
Gigoux M; Holmström MO; Zappasodi R; Park JJ; Pourpe S; Bozkus CC; Mangarin LMB; Redmond D; Verma S; Schad S; George MM; Venkatesh D; Ghosh A; Hoyos D; Molvi Z; Kamaz B; Marneth AE; Duke W; Leventhal MJ; Jan M; Ho VT; Hobbs GS; Knudsen TA; Skov V; Kjær L; Larsen TS; Hansen DL; Lindsley RC; Hasselbalch H; Grauslund JH; Lisle TL; Met Ö; Wilkinson P; Greenbaum B; Sepulveda MA; Chan T; Rampal R; Andersen MH; Abdel-Wahab O; Bhardwaj N; Wolchok JD; Mullally A; Merghoub T
Sci Transl Med; 2022 Jun; 14(649):eaba4380. PubMed ID: 35704596
[TBL] [Abstract][Full Text] [Related]
8. High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.
Holmström MO; Ahmad SM; Klausen U; Bendtsen SK; Martinenaite E; Riley CH; Svane IM; Kjær L; Skov V; Ellervik C; Pallisgaard N; Hasselbalch HC; Andersen MH
Blood Cancer J; 2019 Jan; 9(2):8. PubMed ID: 30655510
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
11. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
12. Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms.
Holmström MO; Hasselbalch HC; Andersen MH
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630667
[TBL] [Abstract][Full Text] [Related]
13. Calreticulin mutations in myeloproliferative neoplasms.
Lavi N
Rambam Maimonides Med J; 2014 Oct; 5(4):e0035. PubMed ID: 25386351
[TBL] [Abstract][Full Text] [Related]
14. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
15. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
16. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].
Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090
[No Abstract] [Full Text] [Related]
18. Low
Makarik TV; Abdullaev AO; Nikulina EE; Treglazova SA; Stepanova EE; Subortseva IN; Kovrigina AM; Melikyan AL; Kulikov SM; Sudarikov AB
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33921387
[No Abstract] [Full Text] [Related]
19. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
Wang J; Hao J; He N; Ji C; Ma D
Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
[TBL] [Abstract][Full Text] [Related]
20. Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
Palova M; Szotkowski T; Hlusi A; Indrak K; Navratilova J; Divoka M; Papajik T
Neoplasma; 2018; 65(2):296-303. PubMed ID: 29534592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]